Arimidex 1mg/tab 28 Tabletten by AstraZeneca

Usage

1. Time your start: begin Anastrozole 2–3 days after the last short-ester injection or up to 2 weeks after a long-ester cycle ends, once serum androgens have begun declining.
2. Use a tablet splitter: split the scored 1 mg tablet cleanly to obtain a precise 0.5 mg dose if your protocol calls for lower-end estrogen management.
3. Take with or without food: Anastrozole absorption is not affected by meals, but maintaining a consistent daily timing improves steady-state plasma levels.
4. Combine with your SERM: administer Anastrozole on the same days as Tamoxifen or Clomiphene — both drugs address estrogen from different angles and are pharmacokinetically compatible.
5. Monitor estradiol and testosterone: schedule blood work at PCT weeks 2 and 4; use LC-MS/MS-sensitive estradiol assays, not standard immunoassay panels, for accuracy at low concentrations.
6. Taper, do not stop abruptly: reduce dose progressively in the final week of PCT to allow the aromatase enzyme activity to normalise gradually and avoid a rebound estradiol spike.

Warnings

Frequently asked questions

When exactly should I start taking Anastrozole during Post Cycle Therapy?

Anastrozole should be introduced at PCT start — typically 2–3 days after the last short-ester injection, or up to 2 weeks after the final long-ester dose, once blood androgen levels have declined enough for natural testosterone production to resume. Starting too early may crash estradiol before the body needs it; starting late allows estrogen rebound to suppress LH and FSH output before recovery has begun.

How long should an Anastrozole-based PCT protocol last?

Most PCT protocols using Anastrozole run 4–6 weeks. Recovery speed depends on cycle length, compounds used, and individual HPG axis sensitivity. Blood work at weeks 2 and 4 — measuring LH, FSH, total testosterone, and estradiol — provides objective guidance on whether to extend or taper the protocol. A 6-week cycle typically achieves near-baseline hormone restoration when Anastrozole is correctly dosed.

Should Anastrozole be combined with a SERM during PCT, and why?

Yes — combining Anastrozole with a SERM such as Tamoxifen (Nolvadex) or Clomiphene (Clomid) is the recommended dual-vector approach. Anastrozole reduces total circulating estradiol by inhibiting aromatase, while the SERM blocks estrogen receptors directly at the pituitary, disinhibiting LH and FSH secretion. This two-pronged strategy restores gonadotropin pulsatility more reliably than either drug used alone.

Can Arimidex 1mg tablets be split for lower PCT doses?

Yes — Arimidex 1 mg tablets are scored and can be split to achieve 0.5 mg doses, which is a common PCT titration strategy. Using a clean tablet splitter ensures accurate halving. Many PCT practitioners start at 0.5 mg every other day and adjust based on serum estradiol readings, avoiding the over-suppression that can occur with a fixed 1 mg daily dose.

How is AstraZeneca Arimidex packaged, and does discreet shipping apply?

AstraZeneca Arimidex is supplied in an original pharmaceutical blister pack of 28 tablets (1 mg each), sealed in a labelled carton consistent with prescription-medicine standards. Orders are dispatched in plain, unmarked outer packaging with no product-identifying information on the exterior — ensuring full discretion from dispatch to delivery. (2) angle_used

Manufacturer

AstraZeneca plc is a British-Swedish multinational biopharmaceutical company founded in 1999 through the merger of Astra AB (Sweden) and Zeneca Group (UK). The company is headquartered in Cambridge, United Kingdom, and operates manufacturing and R&D facilities across more than 60 countries. AstraZeneca originally developed and brought anastrozole to market under the Arimidex brand name in 1995 for the treatment of hormone receptor-positive breast cancer in post-menopausal women — making it the originator manufacturer of this compound. This heritage means the pharmaceutical specifications, tablet consistency, and quality control standards embedded in Arimidex 1 mg are derived from decades of oncology-grade production rather than generic approximation. All AstraZeneca manufacturing sites operate under current Good Manufacturing Practice (cGMP) as regulated by the MHRA (UK), EMA (EU), and FDA (US), with each batch subject to validated HPLC potency testing and full chain-of-custody documentation.